What We Should Expect from an Innovative Intra-Articular Hyaluronic Acid Product: Expert Opinion Based on a Comprehensive Review of the Literature.

Autor: Migliore A; Rheumatology Unit, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy., Maheu E; Rheumatology Department, AP-HP, Saint-Antoine Hospital, 75012 Paris, France., Saccone L; Department of Orthopaedics and Traumatology, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy.; Department of Orthopaedics and Traumatology, Fondazione Policlinico Universitario Campus Bio-Medico of Rome, 00128 Rome, Italy., de Campos GC; Department of Orthopaedics and Traumatology, University of Campinas, Saint Paul 13083, Brazil., Alekseeva L; Department of Metabolic Diseases of Bone and Joints, VA Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia., Chevalier X; Department of Rheumatology, Hôpital Henri-Mondor, Université UPEC Paris XII, 94000 Paris, France., Conrozier T; Service de Rhumatologie, Hôpital Nord Franche, 90400 Belfort, France., Crimaldi S; Department of Orthopedic Surgery, Humanitas Research Hospital, 20089 Milan, Italy., Diracoglu D; Department of Physical Medicine and Rehabilitation, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey., Herrero-Beaumont G; Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, 28040 Madrid, Spain., Iolascon G; Department of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', 81100 Caserta, Italy., Ionescu R; Department of Internal Medicine and Rheumatology, University of Medicine & Pharmacy 'Carol Davila', 050474 Bucharest, Romania., Jerosch J; Department of Orthopedic Surgery, Johanna Etienne Hospital, 41462 Neuss, Germany., Laíns J; Physical Rehabilitation Medicine Department, Medical Rehabilitation Centre, Rovisco Pais, 3060-586 Tocha, Portugal.; Faculty Medicine, University of Coimbra, 3004-531 Coimbra, Portugal., Makri S; EUPATI Graduate and Patient Advocate, 1350-410 Brussels, Belgium., Martusevich N; Department of Rheumatology, Belorussian State Medical University, 220116 Minsk, Belarus., Matucci Cerinic M; Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy., Pavelka K; Institute of Rheumatology, 12800 Prague, Czech Republic., J Petrella R; Department of Family Practice and Division of Sport and Exercise Medicine, University of British Columbia, Vancouver, BC V6Z 3B7, Canada., Tarantino U; Department of Orthopaedics and Traumatology, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy., R Bannuru R; Center for Treatment Comparison and Integrative Analysis, Tufts University School of Medicine, Boston, MA 02116, USA.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2023 Nov 30; Vol. 12 (23). Date of Electronic Publication: 2023 Nov 30.
DOI: 10.3390/jcm12237422
Abstrakt: Background: Intra-articular hyaluronic acid (IAHA) products are often used in the treatment of adults with mild-to-moderate knee osteoarthritis (KOA). The International Symposium on Intra-Articular Treatment (ISIAT) convened a multidisciplinary technical expert panel to define characteristics for an innovative IAHA product that should answer unmet needs in the clinical management of adults with mild-to-moderate KOA.
Methods: An initial set of evidence-based statements was developed based on data extracted from articles identified through a comprehensive literature search. A Delphi panel comprising 19 experts in KOA voted in 3 rounds to rate their degree of agreement with accepted statements.
Results: The final set of 13 accepted statements focus on the effect of an innovative IAHA across 5 key domains of nociceptive pain, joint function, quality of life, joint structure and integrity, and adverse effects. The statements set thresholds for clinically meaningful improvements that exceed those generally achievable by currently available IAHA products.
Conclusion: The characteristics described by these statements from the ISIAT set new standards for what should be expected from an innovative IAHA. These statements should serve as a framework for driving the development of innovative IAHA products that will surpass the actual outcomes achieved by current viscosupplements in patients with mild-to-moderate KOA.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje